Abstract
In spite of advances in tuberculosis (TB) chemotherapy, TB is still airborne deadly disorder as a major issue of health concern worldwide today. Extensive researches have been focused to develop nov-el drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing dose-related toxicities and to rectify technologically related drawbacks of anti-tubercular drugs. Moreover, the rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness of the anti-tubercular drugs. This could be achieved by targeting and concentrating the drug on the infection res-ervoir of Mycobacterium. In this article, we briefly compiled the general aspects of Mycobacterium patho-genesis, disease treatment along with progressive updates in novel drug delivery carrier system to enhance therapeutic effects of drug and the high level of patient compliance. Recently developed several vaccines might be shortly available as reported by WHO.
Highlights
World Health Organization (WHO) has recently published that tuberculosis (TB) incidence rate is falling about at 2 % annually which needs to be falling at 4-5% per year by 2020 as per report [1]
We briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system to enhance therapeutic effects of drug and the high level of patient compliance
In this review, we briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system in order to enhance therapeutic effects of drug and the high level of patient compliance
Summary
World Health Organization (WHO) has recently published that tuberculosis (TB) incidence rate is falling about at 2 % annually which needs to be falling at 4-5% per year by 2020 as per report [1]. Extensive drug resistance (XDR) strain is defined as MDR strain including additional resistance to fluoroquinolones and at least two injectable second-line anti-tubercular drugs Both have been identified by the WHO as a major challenge for the treatment of TB. For effective TB treatment of new cases, six-month regimen of first-line anti-TB drugs (Rifampicin, Ethambutol, Isoniazid, and Pyrazinamide) is recommended as initial phase and continued with the continuous phase of treatment. Both MDR-TB and XDR-TB have become a challenge for effective TB treatment on the global front due to relapses and frequent emerging resistance to ATDs drugs. In this review, we briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system in order to enhance therapeutic effects of drug and the high level of patient compliance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
